**Background of CECR5 Antibody**
The CECR5 antibody targets the protein encoded by the *CECR5* gene (Cat Eye Syndrome Chromosome Region Candidate 5), also known as *ADA2* (Adenosine Deaminase 2). This gene, located on chromosome 22. encodes ADA2. a secreted enzyme involved in adenosine metabolism and immune regulation. Unlike the intracellular ADA1. ADA2 is predominantly expressed in myeloid cells and endothelial cells, playing roles in angiogenesis, inflammation, and maintaining vascular integrity.
Mutations in *CECR5/ADA2* are linked to ADA2 deficiency (DADA2), a rare autosomal recessive disorder characterized by vasculopathy, immune dysregulation, and stroke susceptibility. CECR5 antibodies are critical tools for studying ADA2 expression, function, and its pathological role in DADA2 and related conditions like systemic vasculitis or autoimmune disorders.
In research, CECR5 antibodies are used in techniques such as Western blotting, immunohistochemistry, and ELISA to quantify ADA2 levels in tissues or serum, aiding in disease diagnosis and mechanistic studies. They also support drug development by evaluating ADA2-targeted therapies or biomarkers. Recent studies explore ADA2's involvement in tumor microenvironments and metabolic diseases, broadening its clinical relevance. Overall, CECR5 antibodies are vital for advancing understanding of ADA2 biology and its therapeutic potential.